Research Article

Survival in unresectable AJCC stage I and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study

Interventional Radiology, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA

Search for more papers by this author

Nima Kokabi

Interventional Radiology & Image-guided Medicine, Department of Radiology & Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA

Search for more papers by this author

Hasmukh J Prajapati

Interventional Radiology & Image-guided Medicine, Department of Radiology & Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA

Search for more papers by this author

Orrie Close

Interventional Radiology, Department of Radiology, University of Pittsburgh, PA, USA

Search for more papers by this author

Johannes M Ludwig

Interventional Radiology, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA

Search for more papers by this author

Hyun S Kim

*Author for correspondence:

E-mail Address: kevin.kim@yale.edu

Interventional Radiology, Department of Radiology & Biomedical Imaging, Yale University School of Medicine, New Haven, CT, USA

Yale Cancer Center, New Haven Hospital, 333 Cedar Street, New Haven, CT 06510, USA

Search for more papers by this author

Published Online:7 Mar 2016https://doi.org/10.2217/cer.15.54

View article

Abstract

Aim: To evaluate overall survival (OS) in unresectable American Joint Committee on Cancer (AJCC) stage I/II hepatocellular carcinoma (HCC) treated with drug-eluting-bead transarterial chemoembolization (DEB-TACE) versus best supportive care. Materials & methods: OS in consecutive patients with AJCC stage I/II unresectable HCC diagnosed in 2005–2010 who underwent DEB-TACE and similar patients from SEER with no surgery/radiation recommended/performed was evaluated. Results: Median OS from HCC diagnosis was 28.9 months (DEB-TACE) versus 10.0 months (SEER), p < 0.0001. Median OS was 36.3 months (DEB-TACE) versus 12.0 months (SEER) in AJCC I, and 27.9 months (DEB-TACE) versus 10.0 months (SEER) in AJCC II, p < 0.0001. Significant independent prognostic factors for OS were single primary tumor, no vascular invasion, normal α-fetoprotein and DEB-TACE. Conclusion: DEB-TACE in patients with unresectable AJCC stage I/II HCC was a significant independent prognostic factor for greater OS in a population-based study.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1 El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann. Intern. Med. 139(10), 817–823 (2003).Crossref, Medline, Google Scholar
2 El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340(10), 745–750 (1999).Crossref, Medline, CAS, Google Scholar
3 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69–90 (2011).Crossref, Medline, Google Scholar
4 Ikai I, Yamaoka Y, Yamamoto Y et al. Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy. Ann. Surg. 227(3), 433–439 (1998).Crossref, Medline, CAS, Google Scholar
5 Vauthey JN, Lauwers GY, Esnaola NF et al. Simplified staging for hepatocellular carcinoma. J. Clin. Oncol. 20(6), 1527–1536 (2002). • Highlights an evidence-based simplified American Joint Committee on Cancer staging system based on vascular invasion, tumor number and tumor size and incorporates the effect of fibrosis on survival.Crossref, Medline, Google Scholar
6 Bilimoria MM, Lauwers GY, Doherty DA et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch. Surg. 136(5), 528–535 (2001).Crossref, Medline, CAS, Google Scholar
7 Vauthey JN, Ribero D, Abdalla EK et al. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J. Am. Coll. Surg. 204(5), 1016–1027; discussion 1027–1028 (2007).Crossref, Medline, Google Scholar
8 Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J. Clin. Oncol. 18(5), 1094–1101 (2000).Crossref, Medline, CAS, Google Scholar
9 Patrikidou A, Sinapi I, Regnault H et al. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Invest. New Drugs 32(5), 1028–1035 (2014).Crossref, Medline, CAS, Google Scholar
10 Kalva SP, Pectasides M, Liu R et al. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 37(2), 381–387 (2014).Crossref, Medline, Google Scholar
11 Prajapati HJ, Spivey JR, Hanish SI et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann. Oncol. 24(4), 965–973 (2013). • Illustrates median overall survival and progression free survival after drug-eluting bead transarterial chemoembolization, and survival correlation after drug-eluting bead transarterial chemoembolization with imaging criteria responses.Crossref, Medline, CAS, Google Scholar
12 Lammer J, Malagari K, Vogl T et al. Prospective randomized study of doxorubicin eluting bead embolization in the treatment of heptocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol. 33(41), 41–52 (2010).Crossref, Medline, Google Scholar
13 Artinyan A, Mailey B, Sanchez-Luege N et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer 116(5), 1367–1377 (2010). • Highlights differences in hepatocellular carcinoma mortality based on race and other sociodemographic factors.Crossref, Medline, Google Scholar
14 Davila JA, Duan Z, McGlynn KA, El-Serag HB. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: a population-based study in the United States. J. Clin. Gastroenterol. 46(1), 71–77 (2012).Crossref, Medline, Google Scholar
15 El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7), 2557–2576 (2007).Crossref, Medline, CAS, Google Scholar
16 El-Serag HB, Siegel AB, Davila JA et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J. Hepatol. 44(1), 158–166 (2006).Crossref, Medline, Google Scholar
17 Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, Tseng JF. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer 117(5), 1019–1026 (2011).Crossref, Medline, Google Scholar
18 Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, 7th Edition. Springer, NY, USA (2010).Google Scholar
19 Prajapati HJ, Rafi S, El-Rayes BF, Kauh JS, Kooby DA, Kim HS. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. J. Vasc. Interv. Radiol. 23(10), 1286–1293.e1 (2012).Crossref, Medline, Google Scholar
20 Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis. 30(1), 61–74 (2010).Crossref, Medline, CAS, Google Scholar
21 Prajapati HJ, Dhanasekaran R, El-Rayes BF et al. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J. Vasc. Interv. Radiol. 24(3), 307–315 (2013).Crossref, Medline, Google Scholar
22 Bruix J, Sherman M.Management of hepatocellular carcinoma: an update. Hepatology 53(3), 1020–1022 (2011).Crossref, Medline, Google Scholar
23 Davis CR. Interventional radiological treatment of hepatocellular carcinoma. Cancer Control 17(2), 87–99 (2010).Crossref, Medline, Google Scholar
24 Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 15(Suppl. 4), 42–52 (2010).Crossref, Medline, CAS, Google Scholar
25 O'Neil BH, Venook AP. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. Oncologist 12(12), 1425–1432 (2007).Crossref, Medline, Google Scholar
26 Kalva SP, Pectasides M, Liu R et al. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc. Intervent. Radiol. 37(2), 381–387 (2014).Crossref, Medline, Google Scholar
27 Burrel M, Reig M, Forner A et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J. Hepatol. 56(6), 1330–1335 (2012).Crossref, Medline, Google Scholar
28 Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. HPB (Oxford) 12(3), 174–180 (2010).Crossref, Medline, Google Scholar
29 Llado L, Virgili J, Figueras J et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 88(1), 50–57 (2000).Crossref, Medline, CAS, Google Scholar
30 El Khaddari S, Gaudin JL, Abidi H, Picaud G, Rode A, Souquet JC. [Chemoembolization in hepatocellular carcinoma: multivariate analysis of survival prognostic factors after the first session]. Gastroenterol Clin Biol. 26(8–9), 728–734 (2002).Medline, Google Scholar
31 Grieco A, Pompili M, Caminiti G et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54(3), 411–418 (2005).Crossref, Medline, CAS, Google Scholar
32 Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol. Ther. 38(7), 703–712 (2013).Crossref, Medline, CAS, Google Scholar
33 Shaya FT, Breunig IM, Seal B, Mullins CD, Chirikov VV, Hanna N. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare. Pharmacoeconomics 32(1), 63–74 (2014).Crossref, Medline, Google Scholar
34 SEER Cancer Statistics Review, 1975–2010. http://seer.cancer.gov/csr/1975_2010/.Google Scholar

Vol. 5, No. 2

Metrics

Downloaded 142 times

History

Published online 7 March 2016

Published in print March 2016

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download